We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia.
- Authors
Silver, Kevin H.; Newman, Isadore; Rohr, Susan M.; Johnson, Jeremy; Josephson, Richard A.
- Abstract
The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a high loading dose of clopidogrel (thienopyridine) with abciximab (IIb/IIIa receptor inhibitor) prior to coronary intervention. We reviewed the records of 504 patients who underwent PCI at a large tertiary care hospital and noted an incidence of thrombocytopenia of 4.8%, comparable to published historical controls who received abciximab without clopidogrel. In patients undergoing PCI, there was no difference in thrombocytopenia or bleeding complications between patients receiving a high or a low dose of a thienopyridine. We conclude that a high loading dose of a thienopyridine derivative prior to PCI may be administered safely and efficaciously in the setting of concomitant administration of abciximab without an undue risk of thrombocytopenia.
- Subjects
ASPIRIN; HEART diseases; GLYCOPROTEINS; THROMBOCYTOPENIA; BLOOD platelet disorders
- Publication
Ohio Journal of Science, 2005, Vol 105, Issue 4, p74
- ISSN
0030-0950
- Publication type
Article